Sign Up to like & get
recommendations!
3
Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-3461
Abstract: Background: KRAS mutations (mt) are found in ~30% of non-small cell lung cancers (NSCLC). Despite the approval and development of KRAS G12C and KRAS G12D inhibitors respectively, mechanisms of resistance to MAPK pathway inhibitors are…
read more here.
Keywords:
avutometinib everolimus;
kras nsclc;
combination;
mek ... See more keywords